Metastatic Triple-Negative Breast Cancer (mTNBC) Market SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2025-2032)

Metastatic Triple-Negative Breast Cancer (mTNBC) Market is segmented By Therapy (Chemotherapy, Immun...

Metastatic Triple-Negative Breast Cancer (mTNBC) Market Size

Market Size in USD Bn

CAGR5.2%

Study Period2025-2032
Base Year of Estimation2024
CAGR5.2%
Market ConcentrationMedium
Major PlayersG1 Therapeutics, PharmAbcine/Merck, Roche/Genentech, Bristol Myers Squibb, AstraZeneca and Among Others
*Disclaimer: Major players are listed in no particular order.
*Source: Coherent Market Insights
setting-icon
Want to purchase customized report?
please let us know !

Metastatic Triple-Negative Breast Cancer (mTNBC) Market Analysis

The metastatic triple-negative breast cancer (mTNBC) market is estimated to be valued at USD 1.65.2 Bn in 2025 and is expected to reach USD 2.35.2 Bn by 2032, growing at a compound annual growth rate (CAGR) of 5.2% from 2025 to 2032. The increasing incidence of breast cancer worldwide and limited treatment options for mTNBC are major factors driving the growth of this market.

Metastatic Triple-Negative Breast Cancer (mTNBC) Market Report Snapshots

Metastatic Triple-Negative Breast Cancer (mTNBC) Market Size